<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>1521-0103/345/1/69&#226;&#8364;&#8220;75$25.00                                                                                        http://dx.doi.org/10.1124/jpet.112.202481 <br /> THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS                                                      J Pharmacol Exp Ther 345:69&#226;&#8364;&#8220;75, April 2013 <br /> U.S. Government work protected U.S. copyright <br />  <br />  <br />  <br />  <br /> Paclitaxel Ameliorates Lipopolysaccharide-Induced Kidney Injury <br /> by Binding Myeloid Differentiation Protein-2 Block Toll-Like <br /> Receptor 4&#226;&#8364;&#8220;Mediated Nuclear Factor-kB Activation and <br /> Cytokine Production <br />  <br /> Dongshan Zhang, Yijian Li, Yu Liu, Xudong Xiang, Zheng Dong <br /> Departments Emergency Medicine (D.Z., Yi.L., X.X.) Nephrology (Yu.L., Z.D.), Second Xiangya Hospital, Central South <br /> University, Changsha, Hunan, China; Department Cellular Biology Anatomy, Medical College Georgia, Georgia <br /> Regents University, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia (D.Z., Yu.L., Z.D.) <br /> Received December 6, 2012; accepted January 11, 2013 <br />  <br />  <br /> <span id='am-1' about='protege:abstract' typeof='owl:Thing'>ABSTRACT</span> <br /> Recent studies suggest paclitaxel, anticancer agent,           degradation inhibitor kB-a, blocked expression <br /> modulate injury inflammatory responses normal                   activation NF-kB p65. At upstream level, paclitaxel <br /> tissues. However, underlying mechanism fully un-                reduced LPS-induced association myeloid differentiation <br /> derstood. Here examined effect paclitaxel                protein-2 (MD-2) Toll-like receptor 4 (TLR4). In vitro <br /> lipopolysaccharide (LPS)&#226;&#8364;&#8220;induced acute kidney injury (AKI)              assay, paclitaxel shown directly bind recombinant MD-2. <br /> mice studied mechanism. At relatively low doses,           The inhibitory effect paclitaxel NF-kB activation and <br /> paclitaxel protected LPS-induced AKI improved                  cytokine expression disappeared MD-2 knockdown cells, <br /> animal <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-68' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span>survival</span>. The beneficial effects paclitaxel ac-             indicating paclitaxel acts MD-2. Collectively, these <br /> companied downregulation tumor necrosis factor-a,                results suggest paclitaxel bind MD-2 block MD-2/ <br /> interleukin-1, interleukin-6 production. In cultured renal             TLR4 association LPS treatment, resulting the <br /> tubular HK-2 cells, paclitaxel decreased DNA-binding activity          suppression NF-kB activation inhibition proinflam- <br /> of nuclear factor-kB (NF-kB) LPS treatment, inhibited           matory cytokine production. <br />  <br />  <br />  <br />                              Introduction                                    Lipopolysaccharide (LPS) major pathogenic factor <br />                                                                            infection Gram-negative bacteria (Mayeux, 1997; <br />   Gram-negative bacterial infection associated septic                 Karima et al., 1999; Bosshart Heinzelmann, 2007). In <br /> multiple organ failure remains significant cause mor-                 mice animal models, LPS induces AKI, is <br /> bidity mortality patients (Karima et al., 1999; Gao                 accompanied robust inflammatory response including <br /> et al., 2008; Sharma et al., 2008). In kidneys, sepsis induces             leukocyte infiltration (Wang et al., 2009; Zahedi et al., 2010; <br /> acute injury, tissue damage, decrease renal function,               Eadon et al., 2012). Proximal tubular cells thought play <br /> diminishing efficacy fluid supplementation                role interstitial leukocyte infiltration kidneys <br /> therapeutics (Matejovic et al., 2011; Zarjou Agarwal,                  anatomic proximity ability produce pro- <br /> 2011; Mayeux MacMillan-Crow, 2012). Development                     inflammatory mediators chemotactic cytokines (Danoff, <br /> new drugs treat septic acute kidney injury (AKI)              1998; Wan et al., 2008). In cells, nuclear factor-kB <br /> has great potential reduce mortality morbidity                 (NF-kB), ubiquitous proinflammatory transcription fac- <br /> patients (Bagshaw et al., 2009; Zarjou Agarwal, 2011).                 tor, pivotal role regulation cytokines, as <br /> However, up-<span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span>-date, effective therapies septic AKI            interleukin-1 (IL-1) tumor necrosis factor-a (TNF-a), and <br /> available.                                                                 early response genes LPS treatment (Viedt <br />                                                                            et al., 2002; Zager et al., 2007; Wang et al., 2011). <br />                                                                              Paclitaxel anticancer agent stabilizes micro- <br />   This research supported National Natural Science      tubules interfere microtubule breakdown cell <br /> Foundation China [Grant 81100507/H0509]; National Basic Research <br /> Program China 973 Program No. 2012CB517600 [Grant 2012CB517601]; <br />                                                                            division mitosis, resulting cell cycle arrest cell death <br /> the Central South University Free Exploration Research Program [Grant      cancer (Kavallaris, 2010; Rao et al., 2012). However, recent <br /> 2011QNZT172]; National Institutes Health [Grants 2R01-DK58831   research suggests paclitaxel modulate injury <br /> 1R01-DK87843]; US Department Veterans Affairs [Merit Review]. <br />   D.Z. Yi.L. contributed equally work.                         inflammatory response nonmalignant tissues. For <br />   dx.doi.org/10.1124/jpet.112.202481.                                      example, showed low-dose paclitaxel efficiently <br />  <br /> ABBREVIATIONS: AKI, acute kidney injury; BUN, blood urea nitrogen; ELISA, enzyme-linked immunosorbent assay; IL-1, interleukin-1; IL-6, <br /> interleukin-6; LPS, lipopolysaccharide; MD-2, myeloid differentiation protein-2; NF-kB, nuclear factor-kB; OSOM, outer stripe outer medulla; <br /> TLR4, Toll-like receptor 4; TNF-a, tumor necrosis factor-a. <br />  <br />                                                                                                                                                         69 <br />  70       Zhang et al. <br />  <br /> reduce tubulointerstitial fibrosis kidneys inhibiting               constructed standards provided manufacturers. <br /> Smad2/3 activation downregulating miR-192 (Zhang                      Renal cytokine levels normalized protein concentration in <br /> et al., 2010; Sun et al., 2011). In models acute lung                  lysate. Blood urea nitrogen (BUN) creatinine levels measured <br /> injury, paclitaxel attenuate inflammation vascular                using AutoAnalyzer (Roche Diagnostics, Mannheim, Germany). <br /> leak (Chausovsky et al., 2000; Mirzapoiazova et al., 2007). <br /> However, molecular mechanism paclitaxel                      Antibody-Sandwich ELISA Analysis Paclitaxel Binding <br /> modulates inflammation fully understood. LPS                MD-2 <br /> primary ligand Toll-like receptor 4 (TLR4), activating                 Recombinant human MD-2 produced E. coli described <br /> through binding accessory protein myeloid differenti-              previously (Gruber et al., 2004). The method antibody-sandwich <br /> ation protein-2 (MD-2) (Shimazu et al., 1999; Akashi et al.,              ELISA detection binding paclitaxel MD-2 modified <br /> 2000). Interestingly, in vitro binding assays, paclitaxel              previous study (Resman et al., 2008). This method based on <br />                                                                           use mouse monoclonal antibody binds free MD-2, but <br /> was shown bind human murine MD-2 (Zimmer et al., <br />                                                                           LPS-bound MD-2. All antibodies assay purchased <br /> 2008). In view findings, study initiated             Majorbio BioTech Co. Ltd. (Shanghai, China). Briefly, wells <br /> assess low doses paclitaxel block TLR4-                    microtiter plate precoated chicken polyclonal anti- <br /> mediated NF-kB signaling binding MD-2 leading                MD-2 antibody. Recombinant MD-2 added wells 2 mM <br /> attenuation LPS-induced AKI.                                           2 hours incubation. Then 0&#226;&#8364;&#8220;2 mM paclitaxel added the <br />                                                                           wells 2 hours incubation. Finally, mouse anti-MD-2 <br />                                                                           antibody goat anti-mouse IgG conjugated horseradish <br />                   Materials Methods                                   peroxidase added wells. After extensive washes, 2,2&#226;&#8364;&#8482;- <br /> Care Use Laboratory Animals                                        azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS; horserad- <br />                                                                           ish peroxidase substrate) added detect absorbance 420 nm. <br />    Animal experiments performed accordance the <br /> regulations set Institutional Committee Care Use <br /> of Laboratory Animals Second Xiangya Hospital, China. C57BL/6          Immunoprecipitation <br /> mice housed 12-hour light/dark cycle, allowed free        Approximately 500 mg cellular protein immunoprecipitated <br /> access food water.                                                 2 mg antibodies TLR4 (gift Dr. Ruslan Medzhitov, Yale <br />                                                                           University, New Haven, CT) 1 hour 4&#194;&#176;C followed addition <br /> Animal Model                                                              15 ml protein A/G-agarose beads (Santa Cruz Biotechnology) as <br />                                                                           previously described (Ha et al., 2010). The precipitates washed 4 <br />   The mice (male, aged 8&#226;&#8364;&#8220;10 weeks) divided groups: <br />                                                                           times lysis buffer subjected immunoblotting MD-2 and <br /> vehicle (saline) (n 5 24), paclitaxel (n 5 24), LPS (n 5 24), and <br />                                                                           TLR4. <br /> LPS plus paclitaxel (n 5 24). LPS (<span id='am-2' about='protege:FROM' typeof='owl:Thing'>from</span> Escherichia coli O111:B4, <br /> 10 mg/kg; Santa Cruz Biotechnology, Santa Cruz, CA) injected <br /> through tail vein. Paclitaxel (0.15 mg/kg; Sigma-Aldrich,             Histology <br /> Shanghai, China) injected jugular vein. In LPS plus          For histologic analysis, kidney tissues fixed 4% buffered <br /> paclitaxel group, LPS paclitaxel injected simultaneously.        paraformaldehyde embedded paraffin, 3-mm-thick sec- <br /> The control group administered saline. Renal tissues        tions prepared. The sections stained hematox- <br /> harvested various biochemical morphologic studies 16           ylin eosin. Histologic changes cortex outer stripe <br /> hours LPS and/or paclitaxel treatment survival study.    outer medulla (OSOM) scored blinded observer. The <br />                                                                           percentage tubules displayed cellular necrosis, loss brush <br /> Cell Culture Grouping                                                 border, cast formation, vacuolization, tubule dilation scored <br />                                                                           follows: 0 5 none, 1 5 ,10%, 2 5 11&#226;&#8364;&#8220;25%, 3 5 26&#226;&#8364;&#8220;45%, 4 5 46&#226;&#8364;&#8220;75%, <br />    Experiment Protocol 1. HK-2 cells cultured Dulbecco&#226;&#8364;&#8482;s <br />                                                                           5 5 .76% (Miyaji et al., 2003; Brooks et al., 2009). <br /> modified Eagle&#226;&#8364;&#8482;s medium F-12 supplemented 10% fetal bovine <br /> serum atmosphere 5% CO2&#226;&#8364;&#8220;95% air 37&#194;&#176;C. The cells were <br /> plated dishes grown 24 hours reach 90&#226;&#8364;&#8220;100% confluence         Immunoblot Analysis <br /> before divided groups following treatments:          A standard protocol followed immunoblot analysis. Briefly, <br /> control, paclitaxel, LPS (10 mg/ml), LPS plus paclitaxel. After 2   cells treated lysis buffer (Sigma-Aldrich) containing <br /> 24 hours treatment, cells processed various analyses.     phosphatase inhibitors (Calbiochem, Beijing, China). Samples (20 mg) <br /> All experiments carried quadruplicate.                        resolved SDS-PAGE transferred nitrocellulose <br />    Experiment Protocol 2. HK-2 cells plated approxi-              membrane (Amersham International, Buckinghamshire, UK) for <br /> mately 70% density transfection MD-2 small interfering           sequential incubations primary secondary antibodies. Anti- <br /> RNA (siRNA) (CGCAAAGAAGUUAUUUGCCGAGGAU) control                        bodies used included following: mouse monoclonal anti-NF-kB p65, <br /> siRNA (CGCAAGAAUUGGUUUAGCCGAAGAU) (Invitrogen, Carls-                     rabbit polyclonal anti-p-NF-kB p65, rabbit polyclonal anti-TLR4, <br /> bad, CA) using Lipofectamine 2000 24 hours. The effect siRNA    peroxidase-conjugated goat anti-mouse, goat anti-rabbit IgGs were <br /> the expression MD-2 verified immunoblot analysis. After         purchased Santa Cruz Biotechnology. Mouse monoclonal anti- <br /> siRNA transfection, cells cultured 24 hours reach         MD-2 anti-inhibitor kB-a antibodies Abcam <br /> confluence. The cells treated LPS and/or paclitaxel    (Cambridge, MA). <br /> another 24 hours culture medium 20 mM sodium lactate. <br />                                                                           Statistical Analysis <br /> Measurement TNF-a, IL-1, IL-6, Serum Creatinine, <br />                                                                              Data calculated mean 6 S.E.M. One-way analysis of <br /> and Blood Urea Nitrogen                                                   variance followed Tukey&#226;&#8364;&#8482;s post hoc test used compare <br />    Blood samples kidney tissues collected mice       multiple treatment groups. Two-way analysis variance used to <br /> the vivo experiment culture medium collected        assess statistical significance differences multiple <br /> cell culture study. The levels TNF-a, IL-1, IL-6 de-          treatment groups different time points. Kaplan&#226;&#8364;&#8220;Meier analysis (log- <br /> termined using enzyme-linked immunosorbent assay (ELISA) kits          rank test) used record animal survival. Statistical significance <br /> (R&amp;D Systems Inc, Minneapolis, MN). In cases, standard curve        set P , 0.05. <br />                                                                                                          Kidney Protection Paclitaxel          71 <br />  <br />                               Results                                       cell viability analysis (Fig. 4A). ELISA analysis showed that <br />                                                                             LPS induced NF-kB DNA-binding activity HK-2 cells and <br /> Paclitaxel Improves Animal Survival After LPS Treatment <br />                                                                             notably, effect markedly reduced paclitaxel (Fig. <br />   LPS treatment induced animal death 1 day;                   4B). Furthermore, LPS induced expression phospho- <br /> end 4 days, 20&#226;&#8364;&#8220;30% animals survived. Cotreatment                 p65, p65, TLR4 expression, reduced by <br /> with 0.15 mg/kg paclitaxel delayed animal death 8 hours;                 paclitaxel (Fig. 4C). Consistently, expression inhibitor <br /> notably, majority (68%) animals survived group               kB decreased LPS treatment decrease <br /> at end 4 days (Fig. 1).                                              prevented paclitaxel (Fig. 4C). These results were <br />                                                                             verified densitometry analysis immunoblots (Fig. 4, <br /> Paclitaxel Reduces Kidney Injury Renal Dysfunction                      D&#226;&#8364;&#8220;G). <br /> in LPS-Treated Mice <br />   LPS-induced kidney injury shown tubules                     Paclitaxel Attenuates LPS-Induced Interaction between <br /> both renal cortex OSOM. This tubular damage                         MD-2 TLR4 <br /> significantly ameliorated paclitaxel (Fig. 2, A B). To                 A critical upstream event leading NF-kB activation <br /> note, tubular damage observed study appeared                    LPS treatment activation binding MD-2 <br /> more severe previous studies (Wu et al., 2007;                 TLR4. Therefore, examined effect of <br /> Takahashi et al., 2012). Although cause severity              paclitaxel LPS-induced MD-2/TLR4 association co- <br /> unclear, related LPS dosage tested                 immunoprecipitation assay. Briefly, cell lysate immu- <br /> animal husbandry condition. To analyze kidney function,                     noprecipitated anti-TLR4 antibody, followed by <br /> BUN serum creatinine determined. As shown Fig.                  immunoblot detection MD-2 immunoprecipitates. <br /> 2C, LPS induced significant increases BUN serum                 As shown Fig. 5A, LPS stimulation significantly increased <br /> creatinine levels. The increases significantly attenuated              association MD-2 TLR4, reduced <br /> by cotreatment paclitaxel. <br />  <br /> Paclitaxel Decreases Serum Renal TNF-a, IL-1, <br /> and IL-6 Levels LPS-Treated Mice <br />   The effects paclitaxel serum renal TNF-a, IL-1, <br /> and IL-6 determined ELISA. As shown Fig. 3, LPS <br /> induced marked increases levels TNF-a, IL-1, and <br /> IL-6, suppressed paclitaxel. Paclitaxel no <br /> effects TNF-a, IL-1, IL-6 expression control <br /> conditions. <br />  <br /> Paclitaxel Attenuates LPS-Induced NF-kB Activation <br /> in Renal Tubular Epithelial Cells <br />    To understand mechanism paclitaxel blocks <br /> LPS-induced cytokine production (Fig. 3), examined hu- <br /> man renal tubular HK-2 epithelial cells LPS/paclitaxel <br /> treatment. Within 24 hours, 2 mM paclitaxel did have <br /> significant effects viability HK-2 cells shown by <br /> 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide <br />  <br />  <br />  <br />  <br />                                                                             Fig. 2. Effect paclitaxel LPS-induced renal tissue damage, BUN, <br />                                                                             serum creatinine mice. Male C57 mice injected 10 mg/kg <br />                                                                             LPS 0.15 mg/kg paclitaxel. As control, sham group <br />                                                                             injected saline. Kidney tissues blood samples collected <br />                                                                             16 h treatment. (A) Kidney sections stained hematoxylin <br /> Fig. 1. Effect paclitaxel animal survival LPS treatment. Male   eosin review tubular damage. (B) Tubular damage scores kidney <br /> C57 mice injected 10 mg/kg LPS 0.15 mg/kg         cortex OSOM. (C) BUN serum creatinine. Data shown as <br /> paclitaxel. Animal survival recorded indicated time points. #P ,     mean 6 S.E.M. (n = 12). nP , 0.05 versus sham group; #P , 0.05 <br /> 0.05 versus LPS group (n = 12).                                         versus LPS group. Original magnification,  200 A. <br />  72        Zhang et al. <br />  <br />  <br />  <br />  <br /> Fig. 3. Effect paclitaxel LPS-induced expression TNF-a, IL-1, IL-6 serum kidney tissues. Male C57 mice injected 10 mg/kg <br /> LPS 0.15 mg/kg paclitaxel, sham group injected saline. Kidney tissues blood samples collected 16 hours <br /> after treatment ELISA determination TNF-a, IL-1, IL-6. Data presented mean 6 S.E.M. (n = 12). nP , 0.05 versus sham group; #P , <br /> 0.05 versus LPS group. <br />  <br />  <br />  <br /> by paclitaxel. As control, immunoprecipitation                   improves survival. LPS main endotoxin produced <br /> control IgG did result precipitation MD-2 (not shown).            Gram-negative bacteria, does represent the <br /> One possibility paclitaxel block MD-2/TLR4 as-                  entire spectrum pathogenic factors sepsis. In designing <br /> sociation directly binding MD-2. To test this, determined             renoprotective therapeutics treatment AKI, also <br /> the binding paclitaxel MD-2. For purpose, recombi-               important consider injury subsequent kidney <br /> nant human MD-2 incubated monoclonal antibody                    repair. Ideally, therapeutics limit AKI early <br /> that binds free MD-2, paclitaxel-bound MD-2. In               phase promote kidney repair and/or prevent fibrosis <br /> this assay, paclitaxel shown reduce association               progression phase. In regard, paclitaxel may <br /> MD-2 antibody (Fig. 5C), indicating paclitaxel                adversely affect kidney repair, certainly <br /> indeed binds MD-2.                                                       depend dosage used pharmacokinetics of <br />                                                                             paclitaxel. Further preclinical clinical studies need <br /> The Anti-Inflammatory Effect Paclitaxel Depends                          examine usefulness paclitaxel treatment of <br /> on MD-2                                                                     septic AKI. <br />   To determine anti-inflammatory effect                         In LPS-treated mice, ELISA assay demonstrated the <br /> paclitaxel depends MD-2, downregulated MD-2                      inhibitory effect paclitaxel production proinflam- <br /> specific siRNA. As shown Fig. 6A, transfection HK-2 cells             matory cytokines, including TNF-a, IL-1, IL-6. TNF-a <br /> with MD-2 siRNA led marked MD-2 downregulation.                        related cytokines known contribute toxic <br /> Importantly, MD-2 siRNA transfected cells, stimula-                  effect LPS (Beutler Kruys, 1995). However, is <br /> tory effects LPS NF-kB DNA-binding activity cyto-                 controversial regarding effects paclitaxel the <br /> kine expression diminished. In addition, paclitaxel did                expression proinflammatory factors. In isolated murine <br /> not inhibitory effects cells (Fig. 5C),               macrophages, paclitaxel increase TNF-a IL-1 release <br /> suggesting anti-inflammatory effect paclitaxel                  (Ding et al., 1990; Bogdan Ding, 1992). In contrast, <br /> depends MD-2.                                                            taxanes (paclitaxel docetaxel) decrease levels IL-1 <br />                                                                             TNF-a increase levels interferon-g, IL-2, IL-6 <br />                                                                             serum breast cancer patients (Tsavaris et al., 2002). <br />                             Discussion                                      In LPS-induced lung injury, Mirzapoiazova et al. (2007) <br />   Septic AKI major clinical problem leads sig-                 demonstrated paclitaxel reduce serum levels of <br /> nificant mortality. Currently, effective therapies.            cytokines including TNF-a IL-6. Our data consistent <br /> In study, demonstrated cancer therapy                 studies. Although exact reason underlying <br /> drug, paclitaxel, protective effects LPS-induced AKI                 result discrepancy studies unclear, it <br />                                                                                                            Kidney Protection Paclitaxel           73 <br />  <br />  <br />  <br />  <br />                                                                              Fig. 5. (A) Paclitaxel blocks LPS-induced MD-2/TLR4 association. HK-2 <br />                                                                              cells treated 10 mg/ml LPS 2 hours presence absence <br />                                                                              2 mM paclitaxel collect lysate immunoprecipitation using anti- <br />                                                                              TLR4 antibodies. The immunoprecipitates subjected to <br />                                                                              immunoblot analysis TLR4 MD-2. (B) Densitometric analysis of <br />                                                                              MD-2/TLR4 ratio immunoblots immunoprecipitates. nP , <br />                                                                              0.05 versus mock group paclitaxel-only group; #P , 0.05 versus the <br />                                                                              LPS group. The results LPS induced MD-2/TLR4 association <br />                                                                              molecular association suppressed paclitaxel. (C) In vitro <br />                                                                              assay paclitaxel binding MD-2. Antibody-sandwich ELISA was <br />                                                                              conducted described Materials Methods. Decreases in <br />                                                                              absorbance 420 nm indicate binding paclitaxel recombinant <br />                                                                              MD-2. *P , 0.05 versus 0 mM paclitaxel group; &amp;P , 0.05 versus the <br />                                                                              1 mM paclitaxel group. <br />  <br />  <br />  <br />                                                                              leak vivo (Mirzapoiazova et al., 2007). Interestingly, Lee <br />                                                                              colleagues reported paclitaxel, like LPS, able to <br />                                                                              stimulate translocation 50- 65-kDa hetero- <br />                                                                              dimers NF-kB nucleus 70Z/3 pre-B cells; however, <br />                                                                              effect dose dependent requires 5 mM of <br />                                                                              paclitaxel (Lee Jeon, 2001), significantly higher <br />                                                                              effective dosage study. Furthermore, the <br />                                                                              stimulatory effect NF-kB nuclear translocation shown <br />  <br />  <br /> Fig. 4. Effect paclitaxel LPS-induced activation p65, degradation <br /> of IkBa, expression TLR4 HK-2 cells. HK-2 cells treated <br /> with 10 mg/ml LPS presence absence 2 mM paclitaxel. (A) Cell <br /> viability determined MTT assay 24 hours treatment. (B) NF-kB <br /> DNA-binding activity determined ELISA assay 2 hours treatment. <br /> (C) Immunoblot analysis phospho-p65, p65, IkBa, TLR4 expression <br /> in HK-2 cells 2 hours treatment. (a) Representative immunoblot. <br /> (b,c,d,e) Results densitometric analysis. Data presented mean 6 <br /> S.E.M. (n = 6). nP , 0.05 versus mock group paclitaxel-only group; <br /> # <br />   P , 0.05 versus LPS group. IkB-a, inhibitor kB-a. <br />  <br />  <br />  <br /> may related different models doses pacli- <br /> taxel used. For example, chemotherapy dose paclitaxel <br /> (30 mM) used breast cancer patients significantly higher <br /> than used study (2 mM) study by <br /> Mirzapoiazova et al. (10 mM). In addition proinflam- <br /> matory cytokines, interesting test whether <br /> paclitaxel affects expression anti-inflammatory cyto- <br /> kines IL-10. <br />    Mechanistically, results suggest paclitaxel may <br /> suppress TLR4-mediated NF-kB signaling binding MD-2 to <br /> inhibit cytokine production renal tubular cells. Recent                   Fig. 6. Effect MD-2 knockdown LPS-induced NF-kB DNA-binding <br />                                                                              activity expression TNF-a IL-6 levels. HK-2 cells were <br /> studies indicate microtubule stabilization paclitaxel                transfected MD-2 siRNA control siRNA, followed treatment <br /> may interfere effects LPS cell&#226;&#8364;&#8220;cell junc-                     10 mg/ml LPS presence absence 2mM paclitaxel. (A) <br /> tions, microtubules adherence junctions interact                   Immunoblot analysis verify MD-2 knockdown specific siRNA. (B) <br /> dynamically (Bogdan Ding, 1992; Beutler Kruys,                       NF-kB DNA-binding activity determined using ELISA assay. (C D) <br />                                                                              TNF-a IL-1 expression analyzed ELISA assay. Data presented <br /> 1995; Chausovsky et al., 2000). Furthermore, paclitaxel                  mean 6 S.E.M. (n = 6). nP , 0.05 versus mock group; #P , 0.05, <br /> suppress LPS-induced inflammation attenuating vascular                    versus LPS plus control siRNA group. <br />  74          Zhang et al. <br />  <br /> after pre-exposing cells paclitaxel (Lee Jeon, 2001).                          Byrd CA, Bornmann W, Erdjument-Bromage H, Tempst P, Pavletich N, Rosen N, <br />                                                                                             Nathan CF, Ding A (1999) Heat shock protein 90 mediates macrophage acti- <br /> On hand, recent studies suggested                                    vation Taxol bacterial lipopolysaccharide. Proc Natl Acad Sci USA 96: <br /> that LPS paclitaxel share common receptor/signaling                                   5645&#226;&#8364;&#8220;5650. <br />                                                                                           Chausovsky A, Bershadsky AD, Borisy GG (2000) Cadherin-mediated regulation <br /> complex (Byrd et al., 1999; Kawasaki et al., 2000; Lee et al.,                              microtubule dynamics. Nat Cell Biol 2:797&#226;&#8364;&#8220;804. <br /> 2000). In line studies, study provides evidence                            Danoff TM (1998) Chemokines interstitial injury. Kidney Int 53:1807&#226;&#8364;&#8220;1808. <br />                                                                                           Ding AH, Porteu F, Sanchez E, Nathan CF (1990) Shared actions endotoxin <br /> that low doses, paclitaxel suppresses NF-kB signaling                                 taxol TNF receptors TNF release. Science 248:370&#226;&#8364;&#8220;372. <br /> LPS-induced injury mouse kidneys renal tubular                                  Eadon MT, Hack BK, Xu C, Ko B, Toback FG, Cunningham PN (2012) Endo- <br /> HK-2 cells. We showed paclitaxel blocks DNA-                                       toxemia alters tight junction gene protein expression kidney. Am J <br />                                                                                             Physiol Renal Physiol 303:F821&#226;&#8364;&#8220;F830. <br /> binding activity NF-kB, accompanied                                    Gao H, Evans TW, Finney SJ (2008) Bench-to-bedside review: sepsis, severe <br /> inhibition cytokine production LPS treatment. To                                  sepsis septic shock - does nature infecting organism matter? Crit <br />                                                                                             Care 12:213. <br /> investigate underlying mechanisms, showed                                     Gruber A, Mancek M, Wagner H, Kirschning CJ, Jerala R (2004) Structural <br /> paclitaxel inhibits association MD-2 TLR4                                   model MD-2 functional role basic amino acid clusters involved in <br />                                                                                             cellular lipopolysaccharide recognition. J Biol Chem 279:28475&#226;&#8364;&#8220;28482. <br /> during LPS treatment HK-2 cells. MD-2 extracellular                              Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J, Kao RL, Williams DL, Gao X, Li <br /> molecule, which, LPS binding, associates TLR4                                C (2010) TLR2 ligands induce cardioprotection ischaemia/reperfusion in- <br />                                                                                             jury PI3K/Akt-dependent mechanism. Cardiovasc Res 87:694&#226;&#8364;&#8220;703. <br /> a specific region form complex trigger downstream                                 Karima R, Matsumoto S, Higashi H, Matsushima K (1999) The molecular <br /> signaling (Shimazu et al., 1999; Kawasaki et al., 2001). In                             pathogenesis endotoxic shock organ failure. Mol Med Today 5:123&#226;&#8364;&#8220;132. <br />                                                                                           Kavallaris M (2010) Microtubules resistance tubulin-binding agents. Nat Rev <br /> study, MD-2 knockdown suppressed LPS-induced signaling                                      Cancer 10:194&#226;&#8364;&#8220;204. <br /> and cytokine production HK-2 cells. Notably, anti-                                 Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M (2000) <br />                                                                                             Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic <br /> inflammatory effect paclitaxel attenuated MD-2                                    signal transduction Taxol. J Biol Chem 275:2251&#226;&#8364;&#8220;2254. <br /> knockdown cells, indicating paclitaxel functions                             Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M (2001) <br /> MD-2. Using vitro binding assay, verified                                  Involvement TLR4/MD-2 complex species-specific lipopolysaccharide-mimetic <br />                                                                                             signal transduction Taxol. J Endotoxin Res 7:232&#226;&#8364;&#8220;236. <br /> that paclitaxel directly bind recombinant MD-2, sug-                               Lee M Jeon YJ (2001) Paclitaxel-induced immune suppression associated with <br /> gesting paclitaxel bind MD-2 interrupt                                   NF-kappaB activation conventional PKC isotypes lipopolysaccharide- <br />                                                                                             stimulated 70Z/3 pre-B lymphocyte tumor cells. Mol Pharmacol 59:248&#226;&#8364;&#8220;253. <br /> MD-3/TLR4 association LPS treatment. The blockade                                  Lee M, Yea SS, Jeon YJ (2000) Paclitaxel causes mouse splenic lymphocytes to <br /> of MD-2/TLR4 association paclitaxel explains observed                                state hyporesponsive lipopolysaccharide stimulation. Int J Immunopharmacol <br />                                                                                             22:615&#226;&#8364;&#8220;621. <br /> effects paclitaxel downstream proinflammatory re-                                   Matejovic M, Chvojka J, Radej J, Ledvinova L, Karvunidis T, Krouzecky A, <br /> sponses, including inhibition NF-kB activation                                   Novak I (2011) Sepsis acute kidney injury bidirectional. Contrib <br />                                                                                             Nephrol 174:78&#226;&#8364;&#8220;88. <br /> suppression cytokine production. Our observations con-                             Mayeux PR (1997) Pathobiology lipopolysaccharide. J Toxicol Environ Health 51: <br /> sistent previous work suggesting paclitaxel acts                                415&#226;&#8364;&#8220;435. <br />                                                                                           Mayeux PR MacMillan-Crow LA (2012) Pharmacological targets renal <br /> through TLR4/MD2 (Kawasaki et al., 2000). According                                      peritubular microenvironment: implications therapy sepsis-induced acute <br /> these results, paclitaxel acts extracellularly binding MD-2                           kidney injury. Pharmacol Ther 134:139&#226;&#8364;&#8220;155. <br /> to modulate TLR4 signaling. However, paclitaxel known                             Mirzapoiazova T, Kolosova IA, Moreno L, Sammani S, Garcia JG, Verin AD <br />                                                                                             (2007) Suppression endotoxin-induced inflammation taxol. Eur Respir J 30: <br /> to stabilize microtubules exert related cell biologic effects                            429&#226;&#8364;&#8220;435. <br /> intracellularly.                                                                          Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA (2003) Ethyl <br />                                                                                             pyruvate decreases sepsis-induced acute renal failure multiple organ damage <br />    In conclusion, study demonstrates low doses                                  aged mice. Kidney Int 64:1620&#226;&#8364;&#8220;1631. <br /> paclitaxel protect LPS-induced proinflammatory                                Rao CV, Kurkjian CD, Yamada HY (2012) Mitosis-targeting natural products for <br />                                                                                             cancer prevention therapy. Curr Drug Targets 13:1820&#226;&#8364;&#8220;1830. <br /> response kidney injury, suggesting potential use                             Resman N, Gradisar H, Vasl J, Keber MM, Pristovsek P, Jerala R (2008) <br /> chemotherapy drug treatment septic AKI. Mecha-                                    Taxanes inhibit human TLR4 signaling binding MD-2. FEBS Lett 582: <br />                                                                                             3929&#226;&#8364;&#8220;3934. <br /> nistically, paclitaxel directly bind MD-2 block MD-2/                              Sharma U, Rhaleb NE, Pokharel S, Harding P, Rasoul S, Peng H, Carretero OA <br /> TLR4 association, resulting inhibition NF-kB signaling                            (2008) Novel anti-inflammatory mechanisms N-Acetyl-Ser-Asp-Lys-Pro in <br />                                                                                             hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 294: <br /> and consequent production cytokines.                                                     H1226&#226;&#8364;&#8220;H1232. <br />                                                                                           Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M <br /> Authorship Contributions                                                                    (1999) MD-2, molecule confers lipopolysaccharide responsiveness Toll- <br />                                                                                             like receptor 4. J Exp Med 189:1777&#226;&#8364;&#8220;1782. <br />    Participated research design: Zhang.                                                Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L, Liu Y, Zhu X, Zhan M, Yang Y, <br />    Conducted experiments: Zhang, Li, Liu.                                                   et al. (2011) Low-dose paclitaxel ameliorates fibrosis remnant kidney model <br />    Performed data analysis: Zhang, Xiang, Li, Dong.                                         down-regulating miR-192. J Pathol 225:364&#226;&#8364;&#8220;377. <br />                                                                                           Takahashi K, Mizukami H, Kamata K, Inaba W, Kato N, Hibi C, Yagihashi S <br />    Wrote contributed writing manuscript: Zhang, Dong.                      (2012) Amelioration acute kidney injury lipopolysaccharide-induced systemic <br />                                                                                             inflammatory response syndrome aldose reductase inhibitor, fidarestat. <br /> References                                                                                  PLoS ONE 7:e30134. <br /> Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K (2000)            Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Im- <br />   Cutting edge: cell surface expression lipopolysaccharide signaling toll-      mune changes patients advanced breast cancer undergoing chemotherapy <br />   like receptor 4-MD-2 complex mouse peritoneal macrophages. J Immunol 164:              taxanes. Br J Cancer 87:21&#226;&#8364;&#8220;27. <br />   3471&#226;&#8364;&#8220;3475.                                                                              Viedt C, Dechend R, Fei J, H&#195;&#164;nsch GM, Kreuzer J, Orth SR (2002) MCP-1 <br /> Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J,                induces inflammatory activation human tubular epithelial cells: involvement of <br />   Marshall J, Parrillo JE, et al.; Cooperative Antimicrobial Therapy Septic          transcription factors, nuclear factor-kappaB activating protein-1. J Am Soc <br />   Shock (CATSS) Database Research Group (2009) Acute kidney injury septic                Nephrol 13:1534&#226;&#8364;&#8220;1547. <br />   shock: clinical outcomes impact duration hypotension prior initiation   Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R (2008) <br />   antimicrobial therapy. Intensive Care Med 35:871&#226;&#8364;&#8220;881.                                     Pathophysiology septic acute kidney injury: really know? Crit Care <br /> Beutler B Kruys V (1995) Lipopolysaccharide signal transduction, regulation          Med 36(4, Suppl)S198&#226;&#8364;&#8220;S203. <br />   tumor necrosis factor biosynthesis, signaling tumor necrosis factor itself.      Wang W, Bansal S, Falk S, Ljubanovic D, Schrier R (2009) Ghrelin protects mice <br />   J Cardiovasc Pharmacol 25 (Suppl 2):S1&#226;&#8364;&#8220;S8.                                                endotoxemia-induced acute kidney injury. Am J Physiol Renal Physiol 297: <br /> Bogdan C Ding A (1992) Taxol, microtubule-stabilizing antineoplastic agent,           F1032&#226;&#8364;&#8220;F1037. <br />   induces expression tumor necrosis factor alpha interleukin-1 macro-           Wang WM, Chen H, Zhong F, Lu Y, Han L, Chen N (2011) Inhibitory effects of <br />   phages. J Leukoc Biol 52:119&#226;&#8364;&#8220;121.                                                         rosiglitazone lipopolysaccharide-induced inflammation murine model and <br /> Bosshart H Heinzelmann M (2007) Targeting bacterial endotoxin: sides             HK-2 cells. Am J Nephrol 34:152&#226;&#8364;&#8220;162. <br />   coin. Ann N Y Acad Sci 1096:1&#226;&#8364;&#8220;17.                                                     Wu L, Tiwari MM, Messer KJ, Holthoff JH, Gokden N, Brock RW, Mayeux PR <br /> Brooks C, Wei Q, Cho SG, Dong Z (2009) Regulation mitochondrial dynamics             (2007) Peritubular capillary dysfunction renal tubular epithelial cell stress <br />   acute kidney injury cell culture rodent models. J Clin Invest 119:              following lipopolysaccharide administration mice. Am J Physiol Renal Physiol <br />   1275&#226;&#8364;&#8220;1285.                                                                                292:F261&#226;&#8364;&#8220;F268. <br />                                                                                                                    Kidney Protection Paclitaxel           75 <br /> Zager RA, Johnson AC, Geballe A (2007) Gentamicin suppresses endotoxin-          Zimmer SM, Liu J, Clayton JL, Stephens DS, Snyder JP (2008) Paclitaxel <br />   driven TNF-alpha production human mouse proximal tubule cells. Am J           binding human murine MD-2. J Biol Chem 283:27916&#226;&#8364;&#8220;27926. <br />   Physiol Renal Physiol 293:F1373&#226;&#8364;&#8220;F1380. <br /> Zahedi K, Barone S,  <br /> </body></html>